Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Century Therapeutics, Inc. (IPSC)

Century Therapeutics presents nonclinical CNTY-813 data at EASD; IND still due Q4 2026

Neutral Impact 2 of 5 product/contract Written later

Century Therapeutics presented nonclinical data on its iPSC-derived islet replacement therapy CNTY-813 at the European Association for the Study of Diabetes meeting in Milan on October 2, 2026. The company reiterated that its CNTY-813 IND submission remains on track for the fourth quarter of 2026, with initial clinical data expected in the second half of 2027.

Key points

  • Data showed CNTY-813 maintained glycemic control in diabetic mice for over eleven months until graft removal.
  • Five clinical-scale manufacturing batches produced consistent final product, using a 29-day process.
  • IND submission is expected in Q4 2026; initial clinical data are anticipated in 2H 2027.
  • The filing reports no financial results; the update covers preclinical data and development timing only.

The filing

CompanyCentury Therapeutics, Inc. (IPSC)
Form8-K, current report
Filed with the SECOct 2, 2026, 8:18 AM ET
Accession number0001104659-26-113055

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.